Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033

Myasthenia Gravis Treatment Market Overview

The global myasthenia gravis treatment market size was valued at USD 2.11 billion in 2024. It is anticipated to reach from USD 2.26 billion in 2025 to USD 5.69 billion by 2033, growing at a CAGR of 10.05% during the forecast period (2025–2033). The growth of the market is attributed to growing patient population and regulatory support.

Key Market Indicators

• North America dominated the myasthenia gravis treatment industry and accounted for a 50.34% share in 2024.
• Based on type, ocular MG dominates the market, primarily affecting eye muscles, with treatment centered on cholinesterase inhibitors, corticosteroids, and immunosuppressants for symptom relief.
• Based on treatment, autologous HSCT leads the market, using patients’ stem cells with chemotherapy to restore hematopoiesis and immune function in autoimmune conditions.
• Based on end user, the hospital segment held the largest share of approximately 56.23% of the market in 2024, owing to its myasthenia gravis patients need multidisciplinary care during severe crises, driving demand for comprehensive, specialized hospital treatments.

Market Size & Forecast

• 2024 Market Size: USD 2.11 billion
• 2033 Projected Market Size: USD 5.69 billion
• CAGR (2025–2033): 10.05%
• North America: Largest market in 2024
• Asia Pacific: Fastest-growing region

The global myasthenia gravis treatment market is primarily driven by the growing patient pool suffering from this disease. Better diagnostic methods, aging populations, and increased awareness boost market growth. The regulatory bodies' approval of novel drugs and treatment therapies targeting the treatment of myasthenia gravis is also anticipated to augment the market expansion. Moreover, ongoing clinical trials and research and development initiatives are expected to create market expansion opportunities.

Myasthenia gravis is a chronic autoimmune neuromuscular condition marked by weakness and rapid exhaustion of voluntary muscles. This occurs when there is a breakdown in the transmission of signals between neurons and muscles. This condition has the potential to influence individuals across all age groups, although it is more prevalent among women under 40 and men over 60.

Symptoms of this illness include muscular weakness in the arms and legs, double vision, verbal communication, chewing, and swallowing challenges. The management of myasthenia gravis commonly entails a multifaceted approach that includes administering medicines, lifestyle modifications, and sometimes surgery. Healthcare practitioners must closely monitor the effectiveness of treatment, make any adjustments to drugs, and monitor for potential adverse effects or consequences.

Top 4 Key Highlights

• Ocular MG dominates the type segment
• Autologous hematopoietic stem cell transplantation (HSCT) dominates the treatment segment 
• Hospitals dominate the end-user segment 
• North America is the highest shareholder in the global market

To get more insights about this report Download Free Sample Report

Market Growth Factors

Growing Patient Population

Myasthenia Gravis is becoming more common worldwide. According to a study published in the Lancet, the global prevalence of myasthenia gravis is predicted to exceed 700,000 individuals. The high occurrence of this disease can be ascribed to several variables, including improved diagnostic techniques, aging demographics, and increased awareness.

Based on statistics from Our World in Data in 2025 around 830 million peopleaged 65. UN projections suggest this will grow to1.7 billion by 2054. Meanwhile, according to the United Nations life expectancy at birth globally was 73.3 years in 2024 and is expected to rise to 77.0 years by 2050. Consequently, this can result in an increasing number of patients, fueling the need for treatment alternatives.

Regulatory Support

The presence of supportive regulatory regulations and streamlined approval procedures for orphan medications and therapies that specifically address rare diseases such as Myasthenia Gravis encourage pharmaceutical companies to allocate resources towards the advancement of treatments for this ailment, thereby stimulating market expansion.

• For instance, in April 2025, the US Food and Drug Administration (FDA) approved nipocalimab (IMAAVY™), a drug manufactured by Johnson and Johnson, for the treatment of adults with generalized myasthenia gravis (gMG) testing positive for the anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody.

Furthermore, in April 2025, the FDA cleared a prefilled-syringe version of VYVGART Hytrulo produced by argenx, a global immunology-focused biotechnology company headquartered in the Netherlands, allowing many patients including older adults with AChR-positive generalized myasthenia gravis to self-inject at home. This expands access beyond infusion centers and can reduce the logistical burden of repeated clinic visits.

Market Restraint

Limited Awareness

Myasthenia gravis is an uncommon autoimmune condition. Due to its relative rareness, healthcare providers may lack awareness of its symptoms or mistakenly diagnose it as other neuromuscular disorders. Insufficient knowledge about a condition can delay identification, allowing the patient's symptoms to deteriorate, potentially leading to serious illness and a decline in their overall well-being. 

MG may be underdiagnosed in certain instances because of the variety of symptoms and insufficient awareness. Patients may ascribe their symptoms to the process of aging, stress, or other medical disorders, and healthcare providers may not contemplate myasthenia gravis as a potential diagnosis. This can lead to missed chances for early intervention and appropriate treatment, enabling the disease to advance without being controlled. These issues together hinder the growth of the market.

Market Opportunities

Growth in R&d and Clinical Trials

Pharmaceutical businesses, academic institutions, and research organizations are allotting resources to research and development (R&D) and clinical trials to create novel medications, treatments, and treatment methods for Myasthenia Gravis.

In August 2025, cemdisiran monotherapy met both primary and key secondary trial endpoints in the NIMBLE phase III study, showing marked improvement in MG-ADL scores alongside 74% inhibition of complement C5 activity. The financial backing for the cemdisiran Myasthenia Gravis program primarily comes from Regeneron Pharmaceuticals under its collaboration and licensing agreement with Alnylam Pharmaceuticals, another pharmaceutical business and the former plans to file a U.S. regulatory submission by Q1 2026.

Furthermore, in February 2024, researchers will begin a phase 3 trial to assess the effectiveness of a completely human monoclonal antibody as a potential treatment for patients with general myasthenia gravis. According to the researchers, the study will provide crucial assistance for healthcare providers to manage MG, which varies in intensity over time. The FLEX trial aims to investigate the efficacy of batoclimab in meeting the various requirements of patients at different stages of the disease. This includes alleviating symptoms during flares, preventing severe worsening of myasthenic symptoms, and sustaining remission.

Regional Insights

North America is the most significant global myasthenia gravis treatment market shareholder and is expected to expand substantially during the forecast period. The myasthenia gravis treatment market is predominantly driven by North America, primarily due to the region's significant prevalence of MG cases.

The estimated prevalence of myasthenia gravis in the United States is 14 to 20 incidents per 100,000 people, which corresponds to around 36,000 to 60,000 cases in the country. Moreover, there has been an increase in research and development of novel treatment options for myasthenia gravis, and it is expected that favorable outcomes from this research would stimulate market expansion in the region.

• In April 2025, a U.S.–based Phase 2b trial evaluated Descartes-08, an autologous mRNA-engineered CAR-T therapy designed to target BCMA, in patients with generalized myasthenia gravis. Led by investigators at the University of South Florida, the study followed 36 heavily pretreated patients, with 12 providing detailed data.

After treatment, participants showed marked and sustained clinical improvement, with MG-ADL scores dropping by an average of 4.8 at twelve months. The therapy was well tolerated, with a favorable safety profile across a year of follow-up. This trial demonstrates meaningful, real-world progress in applying CAR-T technology to autoimmune disease in the U.S., highlighting its potential to reshape treatment for refractory myasthenia gravis.

Asia Pacific Market Trends

The Asia-Pacific region exhibits significant growth prospects. The expansion of healthcare infrastructure and the growing awareness among individuals drive the adoption of MG treatment. In addition, there has been a notable increase in research and development efforts undertaken by various institutes, organizations, and prominent companies.

• In July 2025, Qi et al. published a case report in BMC Neurology detailing the use of efgartigimod in a patient who developed myasthenia gravis associated with immune checkpoint inhibitor therapy, along with concurrent myositis

The patient developed MG coupled with myositis, triggered by immune checkpoint inhibitors which are cancer therapies known to occasionally provoke severe autoimmune neuromuscular complications.

The patient was treated with efgartigimod, a neonatal Fc receptor (FcRn) blocker that reduces circulating pathological IgG autoantibodies. The treatment led to clinical improvement in neuromuscular symptoms and serves as a significant step forward in the treatment of the disease.

Market Segmentation

Type Insights

The ocular MG segment is anticipated to capture the largest market share. Ocular myasthenia gravis (OMG) is a variant of myasthenia gravis (MG), a neurological condition characterized by weakening and exhaustion of voluntary muscles. Contrary to generalized myasthenia gravis, which impacts many muscle groups in the entire body, ocular myasthenia gravis mainly targets the muscles responsible for controlling eye movement and eyelid function. The management of ocular MG is individualized but often involves using cholinesterase inhibitors as a first-line treatment. A study conducted in Japan discovered that corticosteroids and other immunosuppressants, which are drugs that affect the immune system, can alleviate symptoms of ocular MG either when used alone or in conjunction with cholinesterase inhibitors.

Treatment Insights

The autologous hematopoietic stem cell transplantation (HSCT) segment owns the highest market share. Autologous hematopoietic stem cell transplantation (HSCT) is a medical technique in which a patient's stem cells are collected, usually from bone marrow or peripheral blood. These stem cells are subjected to intense chemotherapy to eradicate dysfunctional immune cells. Subsequently, the collected stem cells are reintroduced into the patient's body, facilitating the regeneration of a fresh immune system that ideally lacks the autoimmune reaction responsible for the condition. Autologous hematopoietic stem cell transplantation (HSCT) aims to reinstate the patient's hematopoiesis and immune system functionality, which may have been impaired due to certain conditions such as myasthenia gravis.

End-Users Insights

The hospital segment dominates the global market. Patients with myasthenia gravis often require hospital treatment when they undergo severe exacerbations or crises. The treatment of myasthenia gravis necessitates a collaborative approach involving various medical specialists such as neurologists, pulmonologists, intensivists, surgeons, nurses, and allied health professionals. This comprehensive care is customized to meet the specific requirements of each patient and is expected to contribute to the growth of the hospital segment.

List of key players in Myasthenia Gravis Treatment Market

1. Valeant Pharmaceuticals International
2. Novartis Pharmaceuticals Corporation
3. Apotex Corporation
4. Teva Pharmaceutical Industries Ltd.
5. RPG Life Sciences
6. Cipla
7. F. Hoffmann Roche La Ltd.
8. Bristol-Myers Squibb Company
9. Biogen Inc.
10. AbbVie Inc.
11. GlaxoSmithKline plc
12. Fresenius Kabi

To get more findings about this report Download Market Share

Recent Developments

• April 2025: Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG). This approval marks a new treatment option for adults and pediatric patients aged 12 and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive.
• March 2025: Alexion, a subsidiary of AstraZeneca, presented new data at the 2025 AAN Annual Meeting. The data reinforced the safety and efficacy profiles of ULTOMIRIS (ravulizumab-cwvz) and SOLIRIS (eculizumab) in treating gMG, with real-world evidence from a global registry highlighting reduced oral corticosteroid burden and hospitalizations in patients receiving these treatments.